Physician profile
Hisham Afa Alrefai
NPI 1811962350
$720,023.25
in general payments reported to CMS, 2019-2025
65 companies · $105K in 2025
The $105K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255K · 2020: $178K · 2021: $55K · 2022: $48K · 2023: $23K · 2024: $56K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Food and Beverage: $21K · Travel and Lodging: $15K · Honoraria: $14K · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,960.17 |
| Food and Beverage | $20,588.70 |
| Travel and Lodging | $15,299.96 |
| Honoraria | $14,125.00 |
| Education | $255.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245,335.26 | 2019-2025 | Ozempic, Rybelsus |
| Insulet Corporation | $120,990.44 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $80,105.46 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $72,524.88 | 2021-2025 | |
| Amgen INC. | $65,303.27 | 2019-2025 | Tepezza |
| Corcept Therapeutics | $50,868.75 | 2019-2025 | Korlym |
| Amarin Pharma, INC. | $47,625.25 | 2019-2023 | |
| Valeritas, INC. | $14,881.55 | 2019 | |
| Medtronic, INC. | $3,522.08 | 2021-2025 | Minimed 780g, Minimed 770g, Intellis Adaptivestim |
| Cequr Corporation | $2,523.44 | 2023-2025 | Cequr Simplicity |
| Tandem Diabetes Care, INC. | $2,026.53 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $1,354.65 | 2021-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,308.55 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Esperion Therapeutics, INC. | $904.46 | 2020-2025 | Nexletol |
| Abbvie INC. | $872.69 | 2019-2025 | Synthroid |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $759.54 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Ibsa Pharma INC. | $744.23 | 2019-2025 | Tirosint, Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $692.90 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $632.46 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $590.44 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $538.50 | 2019-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $498.13 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $475.45 | 2022-2025 | Isturisa |
| Merck Sharp & Dohme LLC | $431.96 | 2019-2023 | Belsomra |
| Horizon Therapeutics Plc | $399.20 | 2022-2023 | Tepezza |
| Pfizer INC. | $389.55 | 2023-2025 | |
| Mannkind Corporation | $368.65 | 2019-2025 | |
| Chiesi USA, INC. | $344.07 | 2025 | Myalept, Mycapssa, Juxtapid |
| Abbott Laboratories | $338.40 | 2019-2021 | |
| Halozyme INC | $301.70 | 2023 | |
| Kyowa Kirin, INC. | $233.21 | 2023-2025 | Crysvita |
| Nestle Healthcare Nutrition INC. | $204.24 | 2022-2023 | |
| Tolmar, INC. | $189.85 | 2023-2025 | Jatenzo |
| Zealand Pharma US, INC. | $166.36 | 2020-2022 | |
| Shire North American Group INC | $131.68 | 2019 | |
| Ascendis Pharma Endocrinology INC | $130.99 | 2023-2025 | Yorvipath |
| Alfasigma USA, INC. | $123.20 | 2022 | |
| Clarus Therapeutics INC. | $120.11 | 2021 | |
| Teleflex LLC | $105.65 | 2023 | Turnpike |
| Amryt Pharma Holdings Ltd | $104.34 | 2021-2023 | Myalept, Mycapssa |
| Globus Medical, INC. | $87.57 | 2025 | Senza |
| Ultragenyx Pharmaceutical INC. | $66.67 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $54.92 | 2023 | Quviviq |
| Grt US Holding, INC. | $53.11 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $52.59 | 2019-2021 | |
| Radius Health, INC. | $49.13 | 2023-2024 | Tymlos |
| Nevro Corp. | $45.47 | 2024 | Senza |
| Vistapharm, INC. | $45.32 | 2021 | |
| Ascensia Diabetes Care US INC. | $42.58 | 2024 | |
| Eusa Pharma (US) LLC | $39.17 | 2022 | |
| Verity Pharmaceuticals INC. | $38.61 | 2024-2025 | Tlando |
| Azurity Pharmaceuticals, INC. | $36.21 | 2023 | Adthyza |
| Amphastar Pharmaceuticals, INC. | $33.23 | 2025 | |
| Currax Pharmaceuticals LLC | $30.05 | 2023 | Nexletol, Nexlizet, Contrave |
| Lilly USA, LLC | $21.70 | 2023 | Jardiance |
| Neurocrine Biosciences, INC. | $20.71 | 2025 | |
| Senseonics, Incorporated | $19.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $18.17 | 2025 | Imcivree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.73 | 2019 | |
| Glaxosmithkline, LLC. | $15.04 | 2025 | Arexvy, Shingrix |
| Lifescan, INC. | $15.01 | 2020 | |
| Vifor Pharma, INC. | $14.54 | 2019 | |
| Madrigal Pharmaceuticals | $14.33 | 2025 | Rezdiffra |
| Eisai INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hisham Alrefai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.